World's Best Scientists 2026 revealed!
Robert F. Kelley

Robert F. Kelley

D-Index & Metrics

Biology and Biochemistry

D-Index
59
Citations
11670
World Ranking
12619
National Ranking
5391

Overview

Robert F. Kelley is affiliated with Genentech in the United States, where their research spans several key areas within biochemistry, genetics, molecular biology, and medicine. Their work focuses particularly on monoclonal and polyclonal antibodies, protein purification and stability, and the study of viral infectious diseases and gene expression in insects. Additional research interests include retinal diseases and treatments, transgenic plants, and diabetes and associated disorders.

The scientist has contributed to the following research topics:

  • Monoclonal and Polyclonal Antibodies Research
  • Protein purification and stability
  • Viral Infectious Diseases and Gene Expression in Insects
  • Retinal Diseases and Treatments
  • Transgenic Plants and Applications
  • Diabetes and associated disorders
  • Pancreatic function and diabetes

Frequent publication venues for their work include:

  • Journal of Pharmaceutical Sciences
  • Molecular Pharmaceutics
  • Biotechnology and Bioengineering
  • mAbs
  • Toxicologic Pathology

Their recent papers highlight several aspects of biochemical and pharmaceutical research:

  • Tailoring translational strength using Kozak sequence variants improves bispecific antibody assembly and reduces product-related impurities in CHO cells, 2020, Biotechnology and Bioengineering
  • Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms, 2022, mAbs
  • Stability Comparison Between Microglassification and Lyophilization Using a Monoclonal Antibody, 2023, Journal of Pharmaceutical Sciences
  • Antibody Format and Serum Disposition Govern Ocular Pharmacokinetics of Intravenously Administered Protein Therapeutics, 2021, Frontiers in Pharmacology
  • An Approach to Bioactivity Assessment for Critical Quality Attribute Identification Based on Antibody-Antigen Complex Structure, 2020, Journal of Pharmaceutical Sciences

Robert F. Kelley has collaborated frequently with several coauthors, indicating consistent partnerships within their research network. Notable frequent collaborators include:

  • Devin B. Tesar (5 joint publications)
  • Susan Crowell (3 joint publications)
  • Wendy Sandoval (2 joint publications)
  • Alavattam Sreedhara (2 joint publications)
  • Yue Wang (2 joint publications)

The subfields of study related to Robert F. Kelley's work cover various specialized areas such as molecular biology, radiology, nuclear medicine and imaging, ophthalmology, biotechnology, and immunology. These subfields reflect a multidisciplinary approach that integrates molecular techniques with clinical applications and imaging modalities.

Overall, Robert F. Kelley's scholarly contributions are situated at the interface of molecular biology and medicine, with a focus on therapeutic proteins and antibody research, emphasizing biochemical stability, pharmacokinetics, and bioactivity assessments within pharmaceutical sciences.

Best Publications

  • IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding

    Sarah G. Hymowitz;Ellen H. Filvaroff;JianPing Yin;James Lee

  • Ubiquitin Chain Editing Revealed by Polyubiquitin Linkage-Specific Antibodies

    Kim Newton;Marissa L. Matsumoto;Ingrid E. Wertz;Donald S. Kirkpatrick

  • High level Escherichia coli expression and production of a bivalent humanized antibody fragment.

    Carter P;Kelley Rf;Rodrigues Ml;Snedecor B

  • Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.

    S.G. Hymowitz;H.W. Christinger;G. Fuh;M.H. Ultsch

  • K11-Linked Polyubiquitination in Cell Cycle Control Revealed by a K11 Linkage-Specific Antibody

    Marissa L. Matsumoto;Katherine E. Wickliffe;Ken C. Dong;Christine Yu

  • Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.

    Robert F. Kelley;Klara Totpal;Stephanie H. Lindstrom;Mary Mathieu

  • Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions

    Narendra B. Bam;Jeffrey L. Cleland;Janet Yang;Mark C. Manning

  • A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL.

    S.G. Hymowitz;M.P. O'Connell;M.H. Ultsch;A. Hurst

  • Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer

    Teemu T. Junttila;Kathryn Parsons;Christine Olsson;Yanmei Lu

  • FAB Assembly and Enrichment in a Monovalent Phage Display System

    Lisa J. Garrard;Maria Yang;Mark P. O'Connell;Robert F. Kelley

  • A strategy for risk mitigation of antibodies with fast clearance

    Isidro Hötzel;Frank-Peter Theil;Lisa J. Bernstein;Saileta Prabhu

  • Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding.

    Sarah G. Hymowitz;Darshana R. Patel;Heidi J.A. Wallweber;Steven Runyon

  • In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability

    Vikas K. Sharma;Thomas W. Patapoff;Bruce Kabakoff;Satyan Pai

  • Thermodynamic analysis of an antibody functional epitope

    Robert F. Kelley;Mark P. O'Connell

  • Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab.

    Mark Ultsch;Jack Bevers;Gerald Nakamura;Richard Vandlen

  • Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site.

    Muller Ya;Ultsch Mh;Kelley Rf;de Vos Am

  • Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells

    Teemu T. Junttila;Ji Li;Jennifer A. Johnston;Maria L. Hristopoulos

  • Replacement of proline-76 with alanine eliminates the slowest kinetic phase in thioredoxin folding.

    Robert F. Kelley;Frederic M. Richards

  • Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code.

    Frederic A. Fellouse;Pierre A. Barthelemy;Robert F. Kelley;Sachdev S. Sidhu

  • Improved Quantitative Mass Spectrometry Methods for Characterizing Complex Ubiquitin Signals

    Lilian Phu;Anita Izrael-Tomasevic;Marissa L. Matsumoto;Daisy J. Bustos

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Robert F. Kelley

Trending Scientists

Recently Published Articles